Free Trial
NASDAQ:IMVT

Immunovant (IMVT) Stock Price, News & Analysis

Immunovant logo
$14.64 +0.19 (+1.28%)
As of 11:13 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Immunovant Stock (NASDAQ:IMVT)

Key Stats

Today's Range
$14.41
$14.89
50-Day Range
$13.31
$21.26
52-Week Range
$12.72
$34.47
Volume
123,335 shs
Average Volume
1.20 million shs
Market Capitalization
$2.49 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.33
Consensus Rating
Moderate Buy

Company Overview

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Immunovant Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
39th Percentile Overall Score

IMVT MarketRank™: 

Immunovant scored higher than 39% of companies evaluated by MarketBeat, and ranked 510th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Immunovant has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Immunovant has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Immunovant's stock forecast and price target.
  • Earnings Growth

    Earnings for Immunovant are expected to decrease in the coming year, from ($2.69) to ($3.08) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Immunovant is -5.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Immunovant is -5.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Immunovant has a P/B Ratio of 6.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Immunovant's valuation and earnings.
  • Percentage of Shares Shorted

    28.85% of the float of Immunovant has been sold short.
  • Short Interest Ratio / Days to Cover

    Immunovant has a short interest ratio ("days to cover") of 11.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Immunovant has recently increased by 24.62%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Immunovant does not currently pay a dividend.

  • Dividend Growth

    Immunovant does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    28.85% of the float of Immunovant has been sold short.
  • Short Interest Ratio / Days to Cover

    Immunovant has a short interest ratio ("days to cover") of 11.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Immunovant has recently increased by 24.62%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Immunovant has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 16 news articles for Immunovant this week, compared to 6 articles on an average week.
  • Search Interest

    Only 13 people have searched for IMVT on MarketBeat in the last 30 days. This is a decrease of -48% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Immunovant insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $690,207.00 in company stock.

  • Percentage Held by Insiders

    Only 5.90% of the stock of Immunovant is held by insiders.

  • Percentage Held by Institutions

    47.08% of the stock of Immunovant is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Immunovant's insider trading history.
Receive IMVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter.

IMVT Stock News Headlines

Trump Orders 'National Digital Asset Stockpile'
‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more traction
Immunovant downgraded to Neutral from Buy at UBS
UBS Downgrades Immunovant (IMVT)
Immunovant appoints Eric Venker as CEO, Girao as CFO
See More Headlines

IMVT Stock Analysis - Frequently Asked Questions

Immunovant's stock was trading at $24.77 at the beginning of 2025. Since then, IMVT shares have decreased by 41.7% and is now trading at $14.45.
View the best growth stocks for 2025 here
.

Immunovant, Inc. (NASDAQ:IMVT) issued its quarterly earnings data on Monday, February, 10th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.68) by $0.08.

Immunovant's top institutional investors include Rhumbline Advisers (0.05%), GAMMA Investing LLC and FNY Investment Advisers LLC. Insiders that own company stock include Sciences Ltd Roivant, Peter Salzmann, Julia G Butchko, Eva Renee Barnett, Frank Torti, William L Macias, Mark S Levine, Jay S Stout, Michael Geffner and Andrew J Fromkin.
View institutional ownership trends
.

Shares of IMVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Immunovant investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), e.l.f. Beauty (ELF) and ServiceNow (NOW).

Company Calendar

Last Earnings
2/10/2025
Today
4/24/2025
Next Earnings (Estimated)
6/04/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IMVT
Fax
N/A
Employees
120
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$38.33
High Stock Price Target
$53.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+165.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-259,340,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$2.08 per share
Price / Book
6.95

Miscellaneous

Free Float
159,839,000
Market Cap
$2.45 billion
Optionable
Optionable
Beta
0.81
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:IMVT) was last updated on 4/24/2025 by MarketBeat.com Staff
From Our Partners